The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting increased capital recycling within the medical technology sector, Blackstone and TPG are exploring the sale of Hologic's surgical division. The firms are targeting a valuation exceeding $4 billion for the unit. According to reports, this strategic divestment aims to pay down debt and return capital to investors following one of the largest leveraged buyouts recorded last year.
This potential transaction occurs amid a broader surge in healthcare M&A activity as private equity firms seek exits from mature assets. A $4 billion valuation represents a robust multiple for Hologic’s surgical assets compared to recent peer transactions, per market data. Blackstone remains a dominant force in this space, managing over $1 trillion in assets, making its divestment strategies a key bellwether for healthcare investment sentiment.
Investors are monitoring BX shares, which stood at $118.62 at close July 08, 2026, to gauge the impact of this liquidity event on the firm's balance sheet. Looking ahead, market participants are focused on upcoming US ISM Services PMI data, which could provide critical insights into financing costs and the broader economic trajectory influencing large-scale M&A activity for the remainder of the year.